Dr. Reddy’s Laboratories and UCB, a biopharmaceutical company, have entered into a distribution and co-promotion agreement for Briviact, a brand of brivaracetam. The agreement grants Dr. Reddy’s the exclusive right to distribute Briviact in India.
Briviact (brivaracetam) is approved as an adjunctive therapy for the treatment of partial-onset seizures in epilepsy patients who are 16 years of age and older.
Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.
